TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19776570

Group type: EXPERIMENTAL
Intervention: Rinsing with 20 ml of 100 mg F/l NaF mouthwash after brushing with fluoridated toothpaste (Regime B)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Brushing with 1 g of 1,450 microg F/g NaF toothpaste followed by rinsing for 5 s with 10 ml water (Regime A)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Rinsing with a non-fluoridated mouthwash after brushing with fluoridated toothpaste (Regime C)
Number of subjects: 23
Study: 17688918

Group type: EXPERIMENTAL
Intervention: Modified technique (dissection of bilateral vasa deferentia before placing a retractor)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Previous method (retraction of vasa deferentia with a retractor)
Number of subjects: 321
Study: 15378665

Group type: EXPERIMENTAL
Intervention: Ondamtanggamibang (Korean traditional herbal remedy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 40
Study: 11835723

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia therapy (MHT) for 4-10 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (routine treatment)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia therapy (MHT)
Number of subjects: 60
Study: 9631161

Group type: EXPERIMENTAL
Intervention: Receiving blood cholesterol test results at pretest
Number of subjects: 500

Group type: COMPARATOR
Intervention: Not receiving blood cholesterol test results (control group)
Number of subjects: 500
Study: 7883414

Group type: EXPERIMENTAL
Intervention: Azelastin HCL
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 28
Study: 2889460

Group type: EXPERIMENTAL
Intervention: Xamoterol 200 mg orally once daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Xamoterol 400 mg orally once daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Xamoterol 600 mg orally once daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Xamoterol (all doses)
Number of subjects: 9
Study: 29544720

Group type: EXPERIMENTAL
Intervention: 100 μg of morphine (M100)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 200 μg of morphine (M200)
Number of subjects: 40
Study: 26988367

Group type: EXPERIMENTAL
Intervention: Home-based physical activity intervention
Number of subjects: 80
Study: 23404669

Group type: EXPERIMENTAL
Intervention: Family Foundations intervention (a series of eight classes targeting the coparenting relationship)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 169
Study: 22890714

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) infusion in older sedentary individuals (OS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) infusion in older active individuals (OA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) infusion in young sedentary individuals (Y)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Leg exercise at 12 W in older sedentary individuals (OS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lifelong physical activity in older active individuals (OA)
Number of subjects: 24
Study: 20135144

Group type: EXPERIMENTAL
Intervention: Spray bottle (SB)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 7
Study: 18056004

Group type: EXPERIMENTAL
Intervention: G-CSF from day 6 after induction chemotherapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: G-CSF from day 12 after induction chemotherapy
Number of subjects: 66
Study: 16260969

Group type: EXPERIMENTAL
Intervention: Bisoprolol (Bi)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 16
Study: 12127639

Group type: EXPERIMENTAL
Intervention: Intra-amniotic injection of 40 mg PGF2alpha
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravaginal application of 200 mcg misoprostol (12 hourly doses, max 4 doses)
Number of subjects: 100
Study: 7572582

Group type: EXPERIMENTAL
Intervention: Mibefradil 25 mg
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Mibefradil 150 mg
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 2144618

Group type: EXPERIMENTAL
Intervention: Mini Wright Peak Flow Meter
Number of subjects: 1566

Group type: COMPARATOR
Intervention: Spirometer
Number of subjects: 1566
Study: 630793

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) 100 mg with concurrent lithium therapy (900 mg/day for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorpromazine (CPZ) 100 mg without concurrent lithium therapy
Number of subjects: 0
Study: 30700408

Group type: EXPERIMENTAL
Intervention: Scribes
Number of subjects: 88

Group type: COMPARATOR
Intervention: Non-scribed shifts
Number of subjects: 88
Study: 28233424

Group type: EXPERIMENTAL
Intervention: Glibenclamide (sulfonylurea)
Number of subjects: 747
Study: 27130927

Group type: EXPERIMENTAL
Intervention: FIFA 11 for Health
Number of subjects: 546

Group type: COMPARATOR
Intervention: Regular school PE activities
Number of subjects: 546
Study: 23838763

Group type: EXPERIMENTAL
Intervention: Shock-absorbing flooring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard hospital flooring
Number of subjects: 0
Study: 21851587

Group type: EXPERIMENTAL
Intervention: Active electronic games
Number of subjects: 30

Group type: COMPARATOR
Intervention: No active electronic games
Number of subjects: 30
Study: 19624698

Group type: EXPERIMENTAL
Intervention: Intervention schools (oral health promotion programme)
Number of subjects: 1358

Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 1358
Study: 17270678

Group type: EXPERIMENTAL
Intervention: Visually impaired individuals (binocular acuity less than 6/18)
Number of subjects: 13900

Group type: COMPARATOR
Intervention: People with good vision
Number of subjects: 13900
Study: 15093884

Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 1232
Study: 11691667

Group type: EXPERIMENTAL
Intervention: Homeless
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control
Number of subjects: 252
Study: 9660419

Group type: EXPERIMENTAL
Intervention: Standard long protocol of SC leuprolide acetate (group L)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Monthly injection of leuprolide acetate depot for 4 months (group D)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (L and D)
Number of subjects: 60
Study: 8005563

Group type: EXPERIMENTAL
Intervention: Pirenzepine (PZ) low dose (50 mg at 22 h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pirenzepine (PZ) high dose (50 mg at 8 h plus 100 mg at 22 h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study: 2801097

Group type: EXPERIMENTAL
Intervention: Lens drain
Number of subjects: 72

Group type: COMPARATOR
Intervention: Donaldson drain
Number of subjects: 72
Study: 805388

Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg per day
Number of subjects: 0
Study: 31603293

Group type: EXPERIMENTAL
Intervention: Lower extremity skeletal muscle mass index (LESMI) measured volumetrically and cross-sectionally
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cross-sectional single-slice CT measurements
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Interobserver reliability of cross-sectional slice segmentation
Number of subjects: 100
Study: 28314551

Group type: EXPERIMENTAL
Intervention: Pain presence in fatigued patients with type 1 diabetes
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Muscle, joint and back pain, and headache
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison of patients with pain vs. without pain
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pain and fatigue severity
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Impact of pain
Number of subjects: 120
Study: 25691361

Group type: EXPERIMENTAL
Intervention: Models of survivorship care proposed and described in eight articles.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Survivorship models of care reported in six articles.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 14
Study: 23254227

Group type: EXPERIMENTAL
Intervention: MET+CBT+CM(Abstinence)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: MET+CBT+CM(Homework)
Number of subjects: 215

Group type: COMPARATOR
Intervention: CaseM
Number of subjects: 215
Study: 21911864

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (80% VO2max)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (60% VO2max)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (40% VO2max)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (rest for 30 min)
Number of subjects: 12
Study: 19706911

Group type: EXPERIMENTAL
Intervention: Prednisolone plus albendazole
Number of subjects: 104

Group type: COMPARATOR
Intervention: Prednisolone alone
Number of subjects: 104
Study: 16434669

Group type: EXPERIMENTAL
Intervention: Timcodar dimesylate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15379794

Group type: EXPERIMENTAL
Intervention: Tourniquet with Soffban skin protection
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tourniquet with Atlantech skin protection drape
Number of subjects: 150

Group type: COMPARATOR
Intervention: Tourniquet without skin protection
Number of subjects: 150
Study: 11422755

Group type: EXPERIMENTAL
Intervention: Captopril (average 74 mg/day, range 12.5 to 125 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no treatment with captopril)
Number of subjects: 32
Study: 8996291

Group type: EXPERIMENTAL
Intervention: Aspirin plus ticlopidine (antiplatelet therapy)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Intense anticoagulant therapy (control)
Number of subjects: 123
Study: 7949904

Group type: EXPERIMENTAL
Intervention: Physician reminders for cervical cancer screening
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Physician reminders for tetanus immunization
Number of subjects: 3
Study: 3399330

Group type: EXPERIMENTAL
Intervention: Monocular stimulation by one shadow
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Monocular stimulation by two shadows
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Binocular stimulation by two shadows
Number of subjects: 52
Study: 31977833

Group type: EXPERIMENTAL
Intervention: Energy gel ingestion every 30 minutes (T1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Energy gel ingestion every 45 minutes (T2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No gel ingested during exercise (T3)
Number of subjects: 10
Study: 30698050

Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Lower body muscle strength at baseline
Number of subjects: 82
Study: 27847244

Group type: EXPERIMENTAL
Intervention: Cross-body stretch with scapular stabilization
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cross-body stretch without scapular stabilization
Number of subjects: 20
Study: 25319120

Group type: EXPERIMENTAL
Intervention: Canrenone 50 mg once a day for 3 months, then 50 mg twice a day
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Canrenone
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 23165696

Group type: EXPERIMENTAL
Intervention: GEn 1200 mg
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: GEn 1800 mg
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: GEn 2400 mg
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: GEn 3000 mg
Number of subjects: 523

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study: 21035362

Group type: EXPERIMENTAL
Intervention: Ketoprofen 4mg/kg
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Ketoprofen 2mg/kg
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study: 18469255

Group type: EXPERIMENTAL
Intervention: Daidzein-7-O-beta-d-glucoside (DG) (1 mg DAI aglycone equivalent/kg body weight)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Daidzein (DAI) (1 mg DAI aglycone equivalent/kg body weight)
Number of subjects: 7
Study: 16410347

Group type: EXPERIMENTAL
Intervention: Mendelian randomization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 0
Study: 12587824

Group type: EXPERIMENTAL
Intervention: High avidity anti-dsDNA antibodies in SLE patients
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Patients with renal involvement
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: ELISA method for anti-dsDNA antibody avidity determination
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: ECLAM activity index score
Number of subjects: 101
Study: 11173719

Group type: EXPERIMENTAL
Intervention: Humalog Mix25
Number of subjects: 177

Group type: COMPARATOR
Intervention: Human insulin 30/70
Number of subjects: 177
Study: 9417494

Group type: EXPERIMENTAL
Intervention: Sodium selenite treatment over a period of 28 days
Number of subjects: 40
Study: 8338056

Group type: EXPERIMENTAL
Intervention: Intensive neoadjuvant chemotherapy regimen (FEC-HD) repeated every 21 days
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intensive neoadjuvant chemotherapy regimen (FEC-HD)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intensive neoadjuvant chemotherapy regimen (FEC-HD) followed by modified radical mastectomy or radiotherapy
Number of subjects: 45
Study: 3552076

Group type: COMPARATOR
Intervention: 7 + 3 regimen (7 days of cytosine arabinoside and 3 days of daunorubicin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensified regimen (addition of 6‐thioguanine or extension of cytosine arabinoside to 10 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole antibacterial prophylaxis during remission induction phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discontinue all treatment after 8 months of maintenance chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continue maintenance therapy for a total of 3 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discontinue all therapy at 8 months
Number of subjects: 0
Study: 29234954

Group type: EXPERIMENTAL
Intervention: Low volume (20-25 μl)
Number of subjects: 236

Group type: COMPARATOR
Intervention: High volume (40-45 μl)
Number of subjects: 236
Study: 27032107

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 46
Study: 25595508

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Staff unblinding
Number of subjects: 30

Group type: COMPARATOR
Intervention: Staff identification of treatment device
Number of subjects: 30
Study: 23389554

Group type: EXPERIMENTAL
Intervention: Inspiratory resistance training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isocapnic hyperpnoea
Number of subjects: 24

Group type: COMPARATOR
Intervention: Incentive spirometry (placebo)
Number of subjects: 24
Study: 20591499

Group type: EXPERIMENTAL
Intervention: COMT Val158 genotype (Val homozygote)
Number of subjects: 161

Group type: COMPARATOR
Intervention: COMT Met homozygote genotype
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: COMT genotype (Val and Met)
Number of subjects: 161
Study: 18714150

Group type: EXPERIMENTAL
Intervention: Spirulina (8 g/day for 16 weeks)
Number of subjects: 78
Study: 17361594

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (wavelength 904 nm, frequency 4000 Hz, at dose 2J per point); TENS (frequency 80 Hz, 30 minutes, pulse duration 200 micros); exercise; conventional therapy with NSAIDs (meloxicam, 15 mg per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Meloxicam (15 mg per day)
Number of subjects: 60
Study: 12958684

Group type: EXPERIMENTAL
Intervention: Intraabdominal pressure at 10 mmHg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intraabdominal pressure at 15 mmHg
Number of subjects: 24
Study: 11071328

Group type: EXPERIMENTAL
Intervention: Octreotide (100 microg daily, subcutaneously for the first 10 postoperative days)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (no octreotide)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Octreotide (in 20 patients with total tube drainage)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (in 20 patients with total tube drainage)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Octreotide (during postoperative days 6-10)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (during postoperative days 11-15)
Number of subjects: 43
Study: 8636179

Group type: EXPERIMENTAL
Intervention: PCA-cups
Number of subjects: 120

Group type: COMPARATOR
Intervention: RM-polyethylene cups
Number of subjects: 120
Study: 1418029

Group type: EXPERIMENTAL
Intervention: IX 800 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IX 1,200 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 6388801

Group type: EXPERIMENTAL
Intervention: Three MOPP cycles before irradiation
Number of subjects: 121

Group type: COMPARATOR
Intervention: Six MOPP cycles before irradiation
Number of subjects: 121
Study: 31798713

Group type: EXPERIMENTAL
Intervention: High dose oral cholecalciferol [2,000 IU per day] (experimental group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard treatment without supplementation (control group)
Number of subjects: 42
Study: 30282391

Group type: EXPERIMENTAL
Intervention: High-voltage pulsed radiofrequency (PRF) treatment at 42°C for 360 seconds, followed by lidocaine and normal saline injection.
Number of subjects: 134

Group type: COMPARATOR
Intervention: Nerve block treatment with 1.4 mL of a mixture of dexamethasone and lidocaine after 360 seconds of sham PRF treatment, followed by 0.5 mL of normal saline.
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: High-voltage pulsed radiofrequency (PRF) treatment.
Number of subjects: 134

Group type: COMPARATOR
Intervention: Nerve block treatment.
Number of subjects: 134
Study: 26701831

Group type: EXPERIMENTAL
Intervention: PumpTune settings
Number of subjects: 22

Group type: COMPARATOR
Intervention: Clinician settings
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: PumpTune settings and Clinician settings
Number of subjects: 22
Study: 25015912

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg daily
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 22910901

Group type: EXPERIMENTAL
Intervention: Prosaccades in two-response blocks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antisaccades in two-response blocks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arrow-cued saccades in two-response blocks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Number-cued saccades in two-response blocks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prosaccades with increased response alternatives (from two to six)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arrow-cued saccades with increased response alternatives (from two to six)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Number-cued saccades with increased response alternatives (from two to six)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antisaccades with increased response alternatives (from two to six)
Number of subjects: 0
Study: 20946621

Group type: EXPERIMENTAL
Intervention: Active physiotherapy treatment (manual therapy and exercise plus education and advice)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo treatment (sham ultrasound and non‐therapeutic gel)
Number of subjects: 128
Study: 17288625

Group type: EXPERIMENTAL
Intervention: Internet-tailored advice and brief dietary counselling
Number of subjects: 486

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 486
Study: 16128939

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 150

Group type: COMPARATOR
Intervention: Midazolam plus Meperidine
Number of subjects: 150
Study: 12154207

Group type: EXPERIMENTAL
Intervention: Leflunomide (100 mg initially, then 20 mg/day)
Number of subjects: 1817

Group type: EXPERIMENTAL
Intervention: Methotrexate (15-20 mg/day)
Number of subjects: 1817

Group type: EXPERIMENTAL
Intervention: Sulphasalazine (2 g/day)
Number of subjects: 1817

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1817
Study: 10591720

Group type: EXPERIMENTAL
Intervention: Hospital at home
Number of subjects: 199

Group type: COMPARATOR
Intervention: Hospital ward
Number of subjects: 199
Study: 7767451

Group type: EXPERIMENTAL
Intervention: Early mobilization in an ankle brace (1-2 weeks after surgery)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Postoperative immobilization in a plaster cast for 6 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Early mobilization in an ankle brace
Number of subjects: 30
Study: 2394119

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Glycopyrrolate
Number of subjects: 44
Study: 7018680

Group type: EXPERIMENTAL
Intervention: Combination vinblastine-CCNU
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Single-agent triazinate
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Single-agent dactinomycin
Number of subjects: 133
Study: 30478814

Group type: EXPERIMENTAL
Intervention: DSCT flash caudo‐cranial acquisition (P2)
Number of subjects: 60
Study: 28508568

Group type: EXPERIMENTAL
Intervention: Pressure sensing system with real-time visual feedback
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard mask fitting procedures
Number of subjects: 30
Study: 25980570

Group type: EXPERIMENTAL
Intervention: Pulmonary-specific Quality-of-Life Scale (PQLS)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 389
Study: 24399187

Group type: EXPERIMENTAL
Intervention: Cleansing formulation only (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cleansing solution and moisturizing solution (Group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cleansing formulation and moisturizing formulation (Group 3)
Number of subjects: 60
Study: 21415069

Group type: EXPERIMENTAL
Intervention: Plasma renin activity (PRA) in the highest fifth of the PRA distribution
Number of subjects: 2913

Group type: EXPERIMENTAL
Intervention: Baseline PRA measurement
Number of subjects: 2913